Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA) (CISTA)
Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Brest, France, 29609
- CHU de Brest
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with PJI defined according to the IDSA.
- Infection must be mono-microbial or multi-microbial with Staphylococcus spp sensitive to Clindamycin.
- Infection may be acute or chronic, nosocomial or community-acquired.
- Patient having received a curative treatment with Clindamycin.
Exclusion Criteria:
- Patients with osteitis, osteomyelitis, septic arthritis in native joints, diabetic foot infections, spondylodiscitis, infections in external fixator, surgical site infections following neurosurgical management, bedsores, skin and soft tissue infections.
- Patients with mono-microbial infections other than Staphylococcus, multi-microbial infections including other bacteria than Staphylococcus, suspected Osteoarticular Infection without microbial identification.
- Patients with clindamycin-resistant Staphylococcal PJI, constitutive MLSb phenotype.
- Patients having received suspensive treatment with Clindamycin.
- Patients treated with Clindamycin as last line of treatment for a duration of less than 14 days.
- Patients refusing to participate
- Patients under legal protection (guardianship, curatorship, ..)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Clindamycin and Rifampicin
Patients treated with Clindamycin and Rifampicin
|
|
Clindamycin and Fluoroquinolone
Patients treated with Clindamycin and Fluoroquinolone
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Failure of Clindamycine
Time Frame: within 2 years of the diagnosis (within one year for patients diagnosed in December 2019)
|
New diagnosis of PJI at the same site, caused by the same microbial agent
|
within 2 years of the diagnosis (within one year for patients diagnosed in December 2019)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety of Clindamycin
Time Frame: During the treatment and 6 month after
|
Safety of Clindamycin in the treatment of PJI
|
During the treatment and 6 month after
|
|
Correlation between failure of Clindamycin and blood level of Clindamycin
Time Frame: within 2 years of the diagnosis (within one year for patients diagnosed in December 2019)
|
within 2 years of the diagnosis (within one year for patients diagnosed in December 2019)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CISTA - 29BRC21.0123
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.